Sumary of Milvexian helps prevent VTE without raising bleeding after knee arthroplasty:
- November 15, 2021 2 min read Source/Disclosures Published by: Source: Weitz JI, et al.
- Presented at: American Heart Association Scientific Sessions;
- Back to Healio In patients who underwent knee arthroplasty, milvexian, a novel factor XIa inhibitor, was effective at preventing venous thromboembolism and was linked to a low rate of bleeding, researchers reported.
- “Factor XIa is an important driver of postoperative VTE,” Weitz said during the presentation.
- “Postoperative factor XIa inhibition with oral milvexian was effective for prevention of venous thromboembolism and was associated with a low risk of bleeding,” Weitz told Healio.
- “The safety of milvexian when given on top of dual or single antiplatelet therapy is under investigation in the ongoing AXIOMATIC SSP trial,” he said.
- “Further studies are needed to determine whether oral anticoagulants targeting factor XIa can dissociate thrombosis from hemostasis.
- ” Reference: Perspective Back to Top Roxana Mehran, MD This phase 2a study was the first time analyzing preoperative Factor XIa inhibition for VTE prophylaxis.